Zydus Cadila, a leading pharmaceutical company, announced this morning the launch of Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) under the brand name of ‘Ujvira’.
HER2 positive Breast Cancer is considered an aggressive form and constitutes 20 to 25 percent of all Breast Cancers. In a step that can significantly reduce treatment cost by almost 80 percent, the drug is being offered at Rs 32,495 for a 100 mg vial. The current MRP of existing Trastuzumab Emtansine drug is Rs 1,59,225 for 100 mg vial. Ujvira will be available in two strengths, 100 mg and 160 mg.
The formulation is available in two strengths of 100 mg and 160 mg. The price of existing Trastuzumab Emtansine drug stands at Rs. 1,59,225 for a 100 mg vial. On the other hand, the price of ‘Ujvira’ stands at Rs 32,495 for the same strength. This brings down the cost of treatment by almost 80 percent and makes it much more affordable.
This development was impacted positively to share price of Cadila Healthcare Limited which was closed today at Rs 622.75 , up by Rs. 9.60 against the previous closing price of Rs 613.15 on the NSE.
Sensex surges 111 points in early trade; Nifty scaled at 15,197
Now, you can apply LPG cylinder without address proof, know how?
Natco Pharma share price hit One-year-High On Approval of Black Fungus Drug